Ophthalmology CRO Services
KCAS Bio has experience in preclinical ophthalmic research, ranging from identification and procurement of compounds to determining efficacy, tolerability, and PK studies. We give you the milestone data you need to make important decisions in the early stages of your ophthalmologic product development.
Complex ophthalmology studies demand specialist expertise
When developing products for the eye, your project needs a CRO with specialist experience and expertise. Many studies in ophthalmology are complex, and for this reason you need a team which understands the assessments and can focus on the details. KCAS Bio knows how to provide high quality data for your ophthalmology drug development project.
Ophthalmology treatment research, by leading scientists
There are a couple major challenges typically associated with ophthalmology as it relates to bioanalysis, one of the main being limited access to fluids or tissues from a living eye. It is difficult to develop highly sensitive methods when you can’t use a lot of the matrix available. At KCAS Bio, we have a rich history of conducting studies on eye tissues and using unique techniques that make a little sample go a long way in our processes. We have leveraged our rich history of knowing how to build a sensitive method with a minimal amount of volume. Additionally, our pharma team has become well-known for their PK analysis of small molecules, which makes us a perfect candidate for ophthalmological studies, as typically the treatment of the eye is a small molecule.
We employ rigorous quality practices that go beyond our competition. Processes are continuously improved to ensure we consistently deliver a complete outsourcing experience to clients.
KCAS Bio provides high quality science and data services that have benefits for the entire drug development journey.
Agile, responsive, and easy to work with
We prepare and adapt our ophthalmology research based on a deep understanding of your drug development ambitions and wider business objectives.
KCAS Bio scientific insights
Events
August 22
- August 28
KCAS Bio at the 26th International Mass Spectrometry Conference (IMSC 2026) KCAS Bio is excited to attend the 26th International Mass Spectrometry Conference (IMSC 2026), taking place August 22–28, 2026, in Lyon, France. As one of the world’s premier events for mass spectrometry, IMSC brings together…
Blogs
Background on the cancer vaccine program A clinical-stage biotech company approached KCAS Bio to support their oncology immunotherapy program, a first-in-class cancer vaccine leveraging pathogen-derived peptide sequences sharing high homology with disease-associated protein variants expressed in cancer cells. The sponsor wanted to monitor and characterize vaccine-specific immune responses, evaluate…
Blogs
Over the past decade, drug conjugates have emerged as one of the most important innovations in pharmaceutical development. Rather than relying on a drug molecule to find its target on its own, conjugation technologies allow scientists to attach therapeutic payloads to carriers that improve delivery, targeting, stability, and efficacy.
Tell us how we can help with your project
We've earned our reputation for delivering reliable, error-free data. We understand the importance of speed, flexibility, and consistency and only make promises we can keep.